WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John Crowley as its new CEO, the organization announced Tuesday.
Crowley came to biotech when his children were diagnosed with a rare genetic neuromuscular disease. He started working at Bristol Myers Squibb, and started Novazyme, which was eventually successful in creating an enzyme replacement therapy for Pompe disease. He later started and worked for several different biotech companies, most recently with Amicus Therapeutics, which had a drug approved to treat the disease in September.
The trade association’s board chair, Ted Love, served on the board of the company.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect